Severe irreversible bilateral hearing loss after bortezomib (VELCADE®) therapy in a multiple myeloma (MM) patient [1]

Leukemia

Volumn 19, Issue 5, 2005, Pages 869-870

  Engelhardt, M ^a   Muller A M S ^a   Maier, W ^b   Wasch R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CORTICOSTEROID; DEXAMETHASONE; HETASTARCH; MELPHALAN;

ADULT; AUDIOMETRY; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CELL INFILTRATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEARING LOSS; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; NEUTROPENIA; OSTEOSYNTHESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 18644372165     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403723     Document Type: Letter

References (8)

1. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
2. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
3. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 study of two doses of bortezomib in relapsed or refractory. Br J Haematol 2004; 127: 165-172.
4. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-360.
5. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. JCO 2004; 23: 6511, abstract.
6. Antin JH. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med 2002; 347: 36-42.
7. Richardson PG, Briemberg H, Jagannath S, Barlogie B, Berenson J, Singhal S et al. Blood 2003; 102: 512a, abstract.
8. Giasson BI, Lee VM. Are ubiquitination pathways central to Parkinson's disease? Cell 2003; 114: 1-8.